Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8837960 | 0.91 | SLC6A4 (0.59) | SLC6A4HTR1ACYP2D6SCN9AKDM4E | |
| SCHEMBL11949143 | 0.89 | GPR119 (0.45) | GPR119SCN9AKDM4EPKMPDE4A | |
| SCHEMBL11949147 | 0.88 | GPR119 (0.45) | SLC6A4GPR119HTR1ASCN9AKDM4E | |
| SCHEMBL9943153 | 0.88 | HTR1A (0.43) | SLC6A4GPR119HTR1ACYP2D6KDM4E | |
| SCHEMBL8773651 | 0.88 | HTR1A (0.43) | SLC6A4GPR119HTR1ACYP2D6KDM4E | |
| SCHEMBL6115159 | 0.83 | KDM4E (0.47) | SLC6A4GPR119HTR1ACYP2D6KDM4E | |
| SCHEMBL11949137 | 0.82 | GPR119 (0.49) | GPR119SCN9AKDM4EPKM | |
| SCHEMBL11949130 | 0.80 | GPR119 (0.48) | SLC6A4GPR119HTR1AKDM4EPKM | |
| SCHEMBL12128826 | 0.80 | SLC6A4 (0.49) | SLC6A4GPR119HTR1ACYP2D6SCN9A | |
| SCHEMBL6114864 | 0.80 | HTR1A (0.45) | SLC6A4HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778970-B2 | Benzyl piperidine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20120130077-A1 | BENZYL PIPERIDINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130077-A1 | BENZYL PIPERIDINE COMPOUND | HTR1D, HTR1A, HTR1B | SLC6A4 23/4885GPR119 733/4885HTR1A 2/4885 |
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SLC6A4 286/4885GPR119 2104/4885HTR1A 39/4885 |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SLC6A4 286/4885GPR119 2104/4885HTR1A 39/4885 |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SLC6A4 286/4885GPR119 2104/4885HTR1A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.